Evidence map›Paper›PMID 38705492›Full record

ArticleNeurobiology of disease2024

LRRK2 kinase inhibition protects against Parkinson's disease-associated environmental toxicants.

Neda M Ilieva, Eric K Hoffman, Mohammed A Ghalib, J Timothy Greenamyre, Briana R De Miranda

Abstract read
In one paragraph

Article in Neurobiology of disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. A PLAN to address the Parkinson pandemic.Journal of Parkinson's disease · 2025
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Neda M IlievaCenter for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Eric K HoffmanPittsburgh Institute for Neurodegenerative Diseases, Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
Mohammed A GhalibCenter for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
J Timothy GreenamyrePittsburgh Institute for Neurodegenerative Diseases, Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
Briana R De MirandaCenter for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: BrianaDeMiranda@UABMC.edu.

Funding

UAB Alzheimer's Disease Research CenterP30AG086401 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Erik D Roberson · 2024 to 2026
$17.1M
UAB Training Program In NeuroscienceT32NS095775 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Erik D Roberson · 2017 to 2026
$1.6M
Environmental Mitochondrial Toxicants Cause LRRK2 Activation in Parkinson's DiseaseR00ES029986 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DE MIRANDA, BRIANA · 2020 to 2022
$747k
NIA NIH HHS P30 AG086401NIEHS NIH HHS R00 ES029986NINDS NIH HHS T32 NS095775
6 · The paper itself

Abstract

Idiopathic Parkinson's disease (PD) is epidemiologically linked with exposure to toxicants such as pesticides and solvents, which comprise a wide array of chemicals that pollute our environment. While most are structurally distinct, a common cellular target for their toxicity is mitochondrial dysfunction, a key pathological trigger involved in the selective vulnerability of dopaminergic neurons. We and others have shown that environmental mitochondrial toxicants such as the pesticides rotenone and paraquat, and the organic solvent trichloroethylene (TCE) appear to be influenced by the protein LRRK2, a genetic risk factor for PD. As LRRK2 mediates vesicular trafficking and influences endolysosomal function, we postulated that LRRK2 kinase activity may inhibit the autophagic removal of toxicant damaged mitochondria, resulting in elevated oxidative stress. Conversely, we suspected that inhibition of LRRK2, which has been shown to be protective against dopaminergic neurodegeneration caused by mitochondrial toxicants, would reduce the intracellular production of reactive oxygen species (ROS) and prevent mitochondrial toxicity from inducing cell death. To do this, we tested in vitro if genetic or pharmacologic inhibition of LRRK2 (MLi2) protected against ROS caused by four toxicants associated with PD risk - rotenone, paraquat, TCE, and tetrachloroethylene (PERC). In parallel, we assessed if LRRK2 inhibition with MLi2 could protect against TCE-induced toxicity in vivo, in a follow up study from our observation that TCE elevated LRRK2 kinase activity in the nigrostriatal tract of rats prior to dopaminergic neurodegeneration. We found that LRRK2 inhibition blocked toxicant-induced ROS and promoted mitophagy in vitro, and protected against dopaminergic neurodegeneration, neuroinflammation, and mitochondrial damage caused by TCE in vivo. We also found that cells with the LRRK2 G2019S mutation displayed exacerbated levels of toxicant induced ROS, but this was ameliorated by LRRK2 inhibition with MLi2. Collectively, these data support a role for LRRK2 in toxicant-induced mitochondrial dysfunction linked to PD risk through oxidative stress and the autophagic removal of damaged mitochondria.

Indexed as

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Reactive Oxygen SpeciesAnimalsDopaminergic NeuronsEnvironmental PollutantsHumansMitochondriaOxidative StressParaquatParkinson DiseaseRatsRats, Sprague-DawleyRotenoneTrichloroethyleneEnvironmental PollutantsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2ParaquatReactive Oxygen SpeciesRotenoneTrichloroethyleneEnvironmental toxicantsGene x environment (GxE)Leucine rich repeat kinase 2 (LRRK2)MitochondriaParkinson's disease (PD)

Identifiers

PMID38705492
PMCPMC11332574

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.